Total Funding
29
68
Total FundingPre-Seed raised
Growth Score
-3 pts
Heat Score
12 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
93433
Aida uses machine learning and gene expression of individual tumors to help clinicians to prescribe the best drugs for each cancer patient.
Peter Buhl Jensen: Chief Medical OfficerPast Role: Oncology Venture, CEO and Founder
About the Company
Despite massive investment in oncology over the last 30 years, the efficacy of cancer treatments remains stubbornly low. Positive response rates of c.25% (i.e., only 1 in 4 patients) that receive a drug, will benefit from it are typical. New drugs are still being approved with response rates lower than this.
Aida will transform the treatment of
cancer by increasing the positive response rates to more than 50%.
Aida can deliver this via our proprietary algorithmic approach to tumor transcriptome analysis, allowing us to predict a patient’s response to a drug. By predicting on multiple drugs (from one biopsy), we can identify the drugs most likely to have a positive response and enable the doctor to choose the most effective treatment.
